CEN BIOTECH, INC. 2021 EQUITY COMPENSATION PLAN RESTRICTED STOCK AGREEMENTCompensation Plan Restricted Stock Agreement • April 7th, 2021 • Cen Biotech Inc • Pharmaceutical preparations • New York
Contract Type FiledApril 7th, 2021 Company Industry JurisdictionWHEREAS, as of April 2, 2021, the Company adopted the CEN Biotech, Inc. 2021 Equity Compensation Plan (the “Plan”), which Plan authorizes, among other things, the grant of restricted shares of the Company’s common stock (“Common Stock”), to directors, officers and employees of the Company and to other individuals; and
EXECUTIVE EMPLOYMENT AGREEMENT BETWEEN LAWRENCE LEHOUX AND CEN BIOTECH, INC.Executive Employment Agreement • August 31st, 2022 • Cen Biotech Inc • Pharmaceutical preparations • Ontario
Contract Type FiledAugust 31st, 2022 Company Industry JurisdictionThis Executive Employment Agreement (“Agreement”) is entered into as of August 26, 2022, by and between CEN Biotech, Inc. (the “Company”), and Lawrence Lehoux (the “Executive”) and effective as of September 1, 2022 (the “Effective Date”). The parties believe it to be in their best interest to document the terms of the Executive's employment with the Company as follows:
CEN BIOTECH, INC. 2021 EQUITY COMPENSATION PLAN RESTRICTED STOCK AGREEMENTEquity Compensation Plan Restricted Stock Agreement • July 16th, 2021 • Cen Biotech Inc • Pharmaceutical preparations • New York
Contract Type FiledJuly 16th, 2021 Company Industry JurisdictionWHEREAS, as of June 25, 2021, the Company adopted the CEN Biotech, Inc. 2021 Equity Compensation Plan (the “Plan”), which Plan authorizes, among other things, the grant of restricted shares of the Company’s common stock (“Common Stock”), to directors, officers and employees of the Company and to other individuals; and
SETTLEMENT AND RELEASE AGREEMENTSettlement and Release Agreement • April 21st, 2022 • Cen Biotech Inc • Pharmaceutical preparations • New York
Contract Type FiledApril 21st, 2022 Company Industry JurisdictionThis SETTLEMENT AND RELEASE AGREEMENT (the “Agreement”) is entered into as of April 19, 2022, by and between CEN Biotech Inc. (the “Company”) and Ameen Ferris (the “Executive”). The Company and Executive shall collectively be referred to as the “Parties”.
CEN BIOTECH, INC. RESTRICTED STOCK AGREEMENTRestricted Stock Agreement • August 31st, 2022 • Cen Biotech Inc • Pharmaceutical preparations • New York
Contract Type FiledAugust 31st, 2022 Company Industry JurisdictionWHEREAS, as of April 7th, 2021, the Company adopted the CEN Biotech, Inc. 2021 Equity Compensation Plan (the “Plan”), which Plan authorizes, among other things, the grant of restricted shares of the Company’s common stock (“Common Stock”), to directors, officers and employees of the Company and to other individuals; and
CEN BIOTECH, INC. RESTRICTED STOCK AGREEMENTEquity Compensation Plan • August 31st, 2022 • Cen Biotech Inc • Pharmaceutical preparations • New York
Contract Type FiledAugust 31st, 2022 Company Industry JurisdictionWHEREAS, as of April 7th, 2021, the Company adopted the CEN Biotech, Inc. 2021 Equity Compensation Plan (the “Plan”), which Plan authorizes, among other things, the grant of restricted shares of the Company’s common stock (“Common Stock”), to directors, officers and employees of the Company and to other individuals; and
TERMINATION AND RELEASE AGREEMENT Dated as of May 19, 2020Termination and Release Agreement • May 20th, 2020 • Cen Biotech Inc • Pharmaceutical preparations • Ontario
Contract Type FiledMay 20th, 2020 Company Industry JurisdictionThis Termination and Release Agreement (this “Agreement”) is entered into as of the date first set forth above (the “Effective Date”), by and between CEN BIOTECH INC., a corporation incorporated under the laws of Ontario, Canada (the “Purchaser”) and AstralENERGY Solar Manufacturing Corporation, LTD aka AstralENERGY, a corporation incorporated under the laws of Ontario, Canada (the “Vendor”). The Purchaser and the Vendor may be referred to herein individually as a “Party” and collectively as the “Parties.”
THIS IS AN AMENDING AGREEMENT made this 4th day of October, 2018. BETWEEN: CEN BIOTECH INC (Buyer) (herein "CEN") and - STEVAN POKRAJAC and TESLA DIGITAL INC and TESLA DIGITAL GLOBAL GROUP INC (Seller) (herein "PTT”)An Amending Agreement • October 9th, 2018 • Cen Biotech Inc • Pharmaceutical preparations
Contract Type FiledOctober 9th, 2018 Company IndustryAND WHEREAS it is desirous that paragraph 2 of the said Amending Agreement be amended in accordance with the terms herein.
Share Purchase AgreementShare Purchase Agreement • November 30th, 2018 • Cen Biotech Inc • Pharmaceutical preparations
Contract Type FiledNovember 30th, 2018 Company Industry
PATENT PURCHASE AND ASSIGNMENT AGREEMENT BY AND AMONG CEN BIOTECH INC. AND EMERGENCE GLOBAL ENTERPRISES INC.Patent Purchase and Assignment Agreement • May 26th, 2022 • Cen Biotech Inc • Pharmaceutical preparations • British Columbia
Contract Type FiledMay 26th, 2022 Company Industry JurisdictionThis Patent Purchase and Assignment Agreement (this “Agreement”) is entered into as of the date first set forth above (the “Effective Date”) by and between (i) CEN Biotech Inc., a corporation incorporated pursuant to the laws of Ontario, Canada (“Seller”), and (ii) Emergence Global Enterprises Inc., a corporation incorporated pursuant to the laws of British Columbia, Canada (the “Buyer”). Each of the Buyer and Seller may be referred to herein collectively as the “Parties” and separately as a “Party”.
This Agreement to Lease dated this 1st day of October 2017 TENANT (Lessee), Cen Biotech, Inc. (Full legal comes of all Tenants) LANDLORD (Lessor), R&D Labs Canada Inc. (Full legal name of Landlord)Agreement to Lease • April 16th, 2018 • Cen Biotech Inc • Pharmaceutical preparations
Contract Type FiledApril 16th, 2018 Company IndustryThe Tenant hereby offers to lease from the Landlord the premises as described herein on the terms and subject to the conditions as set out in this Agreement.
Share Exchange Agreement by and among CEN Biotech, Inc.; Clear Com Media Inc.; The Shareholders of Clear Com Media Inc.; And Lawrence Lehoux as the Shareholders’ Representative.Share Exchange Agreement • April 20th, 2021 • Cen Biotech Inc • Pharmaceutical preparations • Ontario
Contract Type FiledApril 20th, 2021 Company Industry JurisdictionThis Share Exchange Agreement (this “Agreement”) is entered into as of the date first set forth above (the “Effective Date”) by and between (i) CEN Biotech, Inc. a Corporation incorporated under the laws of Canada, A Canada corporation (the “Company”); (ii) Clear Com Media Inc., an Ontario, Canada corporation (“CCM”), (iii) each of the shareholders of CCM as set forth on the signature pages hereto (the “CCM Shareholders”) and (iv) Lawrence Lehoux as the Representative of the CCM Shareholders (the “Shareholders’ Representative”). Each of CCM and the CCM Shareholders may be referred to collectively herein as the “CCM Parties” and separately as an “CCM Party.” Each of the Company, each CCM Party and the Shareholders’ Representative may be referred to herein collectively as the “Parties” and separately as a “Party.”
TERMINATION AND RELEASE AGREEMENTTermination and Release Agreement • March 29th, 2023 • Cen Biotech Inc • Pharmaceutical preparations
Contract Type FiledMarch 29th, 2023 Company IndustryWHEREAS CEN Biotech Inc. (the "Company"), Clear Com Media Inc. ("CCM"), the shareholders of Clear Com (the "CCM Shareholders") and Lawrence Lehoux (the "Representative") as the CCM Shareholders' representative entered into a Share Exchange Agreement dated as of April 20, 2021 (the "Share Exchange Agreement"), pursuant to which the Company acquired 10,000 shares of CCM Stock (the "Transferred CCM Stock") in exchange for 4,000,000 shares of Company Common Stock (the "Company Stock"), all in accordance with the terms and conditions thereof;
SHARE PURCHASE AGREEMENTShare Purchase Agreement • August 6th, 2018 • Cen Biotech Inc • Pharmaceutical preparations • Ontario
Contract Type FiledAugust 6th, 2018 Company Industry JurisdictionAstralENERGY Solar Manufacturing Corporation, LTD aka AstralENERGY, a corporation incorporated under the laws of Ontario, Canada
Amendment No. 1 To Merger Agreement Dated August 27, 2019Merger Agreement • August 29th, 2019 • Cen Biotech Inc • Pharmaceutical preparations • Wyoming
Contract Type FiledAugust 29th, 2019 Company Industry JurisdictionThis Amendment No. 1 to Merger Agreement (this “Amendment”) is entered into as of the date first set forth above, by and between among (i) Caduceus Software Systems Corp., a Wyoming corporation (“CSOC”), (ii) Caduceus Merger Sub, Inc., a Wyoming corporation and a wholly owned subsidiary of CSOC (“Merger Sub”) and (iii) CEN Biotech, Inc., an Ontario, Canada corporation (“CEN”). CSOC, Merger Sub and CEN may be collectively referred to herein as the “Parties” and individually as a “Party.
Termination of Patent Purchase and Assignment Agreement Dated as of July 19, 2022Purchase and Assignment Agreement • July 20th, 2022 • Cen Biotech Inc • Pharmaceutical preparations
Contract Type FiledJuly 20th, 2022 Company IndustryThis Termination of Patent Purchase and Assignment Agreement (this “Amendment”) is entered into as of the date first set forth above (the “Effective Termination Date”) by and between (i) CEN Biotech Inc., a corporation incorporated pursuant to the laws of Ontario, Canada (“Seller”), and (ii) Emergence Global Enterprises Inc., a corporation incorporated pursuant to the laws of British Columbia, Canada (the “Buyer”). Each of the Buyer and Seller may be referred to herein collectively as the “Parties” and separately as a “Party”.
MUTUAL CONSENT TO TERMINATE AGREEMENTTerminate Agreement • April 16th, 2018 • Cen Biotech Inc • Pharmaceutical preparations
Contract Type FiledApril 16th, 2018 Company IndustryWHEREAS a Commercial Lease Agreement was entered into as of the 1st day of April, 2013, between the Landlord and Creative Edge Nutrition Inc., which Lease was sub-let to Cen Biotech on September 1st, 2013;
Amendment No. 2 To Merger Agreement Dated August 28, 2019Merger Agreement • August 29th, 2019 • Cen Biotech Inc • Pharmaceutical preparations • Wyoming
Contract Type FiledAugust 29th, 2019 Company Industry JurisdictionThis Amendment No. 1 to Merger Agreement (this “Amendment”) is entered into as of the date first set forth above, by and between among (i) Caduceus Software Systems Corp., a Wyoming corporation (“CSOC”), (ii) Caduceus Merger Sub, Inc., a Wyoming corporation and a wholly owned subsidiary of CSOC (“Merger Sub”) and (iii) CEN Biotech, Inc., an Ontario, Canada corporation (“CEN”). CSOC, Merger Sub and CEN may be collectively referred to herein as the “Parties” and individually as a “Party.
Share Purchase AgreementShare Purchase Agreement • December 12th, 2017 • Cen Biotech Inc • Pharmaceutical preparations
Contract Type FiledDecember 12th, 2017 Company Industry
Patent Purchase and Assignment AgreementPatent Purchase and Assignment Agreement • July 20th, 2022 • Cen Biotech Inc • Pharmaceutical preparations • British Columbia
Contract Type FiledJuly 20th, 2022 Company Industry JurisdictionThis Amendment No. 1 to Patent Purchase and Assignment Agreement (this “Amendment”) is entered into as of the date first set forth above (the “Amendment Date”) by and between (i) CEN Biotech Inc., a corporation incorporated pursuant to the laws of Ontario, Canada (“Seller”), and (ii) Emergence Global Enterprises Inc., a corporation incorporated pursuant to the laws of British Columbia, Canada (the “Buyer”). Each of the Buyer and Seller may be referred to herein collectively as the “Parties” and separately as a “Party”.
ContractCen Biotech Inc • June 21st, 2019 • Pharmaceutical preparations
Company FiledJune 21st, 2019 IndustryWINDSOR, ON, June 21, 2019 (NEWSWIRE) – On June 21, 2019, CEN Biotech, Inc. (CEN) entered into a Merger Agreement (the “Merger Agreement”) with Caduceus Software Systems Corp., a Wyoming corporation (“CSOC”), which was reviewed and approved by the Board of Directors of CEN on June 21, 2019. This transaction follows the signing of a Non-Binding Term Sheet with CSOC on May 15, 2019, in which, CEN and CSOC agreed to undertake a merger transaction to combine the two companies’ operations and negotiate and enter into a definite agreement to affect the transaction.
CEN BIOTECH INC. (Buyer)An Amending Agreement • April 8th, 2019 • Cen Biotech Inc • Pharmaceutical preparations
Contract Type FiledApril 8th, 2019 Company IndustryAND WHEREAS it is desirous that paragraph 2 of the said Amending Agreement be amended in accordance with the terms herein.
Terms and Conditions of ServiceCen Biotech Inc • April 8th, 2021 • Pharmaceutical preparations
Company FiledApril 8th, 2021 IndustryThis agreement, between Diego Felipe Rodríguez Velez (herein named as COACH), Director at CONFIEN SAS, and the above-named CLIENT, will begin on April 2st, 2021, and will continue for a minimum of 12 months.
CONTROLLING INTEREST PURCHASE AGREEMENTControlling Interest Purchase Agreement • December 14th, 2017 • Cen Biotech Inc • Pharmaceutical preparations • Ontario
Contract Type FiledDecember 14th, 2017 Company Industry Jurisdiction
Merger Agreement By and Among Caduceus Software Systems Corp., Caduceus Merger Sub, Inc. and CEN Biotech, Inc. Dated as of June 21, 2019Merger Agreement • June 21st, 2019 • Cen Biotech Inc • Pharmaceutical preparations • Wyoming
Contract Type FiledJune 21st, 2019 Company Industry JurisdictionThis Merger Agreement (this “Agreement”), dated as of June 21, 2019 (the “Effective Date”), is entered into by and among (i) Caduceus Software Systems Corp., a Wyoming corporation (“CSOC”), (ii) Caduceus Merger Sub, Inc., a Wyoming corporation and a wholly owned subsidiary of CSOC (“Merger Sub”) and (iii) CEN Biotech, Inc., an Ontario, Canada corporation (“CEN”). CSOC, Merger Sub and CEN may be collectively referred to herein as the “Parties” and individually as a “Party.”
COMMERCIAL LEASE AGREEMENTCommercial Lease Agreement • April 16th, 2018 • Cen Biotech Inc • Pharmaceutical preparations
Contract Type FiledApril 16th, 2018 Company IndustryIN CONSIDERATION OF the Landlord leasing certain premises to the Tenant, the Tenant leasing those premises from the Landlord and the mutual benefits and obligations set forth in this Lease, the receipt and sufficiency of which consideration is hereby acknowledged, the Parties to this Lease (the “Parties”) agree as follows:
THIS IS AN AMENDING AGREEMENT made this 16th day of March, 2020. BETWEEN:An Amending Agreement • March 17th, 2020 • Cen Biotech Inc • Pharmaceutical preparations
Contract Type FiledMarch 17th, 2020 Company IndustryAND WHEREAS it is desirous that paragraph 2 of the said Amending Agreement be amended in accordance with the terms herein.